The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
One Thousand Patients With Primary Myelofibrosis: The Mayo Clinic Experience
Open accessAbstract
OBJECTIVE To share our decades of experience with primary myelofibrosis and underscore the importance of outcomes research studies in designing clinical trials and interpreting their results. PATIENTS AND METHODS One thousand consecutive patients with primary myelofibrosis seen at Mayo Clinic between November 4, 1977, and September 1, 2011, were considered. The International Prognostic Scoring System (IPSS), dynamic IPSS (DIPSS), and DIPSS-plus were applied for risk stratification. Separate analyses were included for patients seen at time of referral (N=1000), at initial diagnosis (N=340), and within or after 1 year of diagnosis (N=660). RESULTS To date, 592 deaths and 68 leukemic transformations have been documented. Parameters at initial diagnosis vs time of referral included median age (66 vs 65 years), male sex (61% vs 62%), red cell transfusion need (24% vs 38%), hemoglobin level less than 10 g/dL (38% vs 54%), platelet count less than 100 × 10(9)/L (18% vs 26%), leukocyte count more than 25 × 10(9)/L (13% vs 16%), marked splenomegaly (21% vs 31%), constitutional symptoms (29% vs 34%), and abnormal karyotype (31% vs 41%). Mutational frequencies were 61% for JAK2V617F, 8% for MPLW515, and 4% for IDH1/2. DIPSS-plus risk distributions at time of referral were 10% low, 15% intermediate-1, 37% intermediate-2, and 37% high. The corresponding median survivals were 17.5, 7.8, 3.6, and 1.8 years vs 20.0, 14.3, 5.3, and 1.7 years for patients younger than 60 years of age. Compared with both DIPSS and IPSS, DIPSS-plus showed better discrimination among risk groups. Five-year leukemic transformation rates were 6% and 21% in low- and high-risk patients, respectively. CONCLUSION The current document should serve as a valuable resource for patients and physicians and provides context for the design and interpretation of clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International scoring system for evaluating prognosis in myelodysplastic syndromes
Greenberg, P., Cox, C., LeBeau, M. M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., et al. (1997) · Blood · doi:10.1182/blood.v89.6.2079 · Cited by 4,427
Vardiman, J. W., Thiele, J., Arber, D. A., Brunning, R. D., Borowitz, M. J., Porwit, A., Harris, N. L., Le Beau, M. M., Hellström-Lindberg, E., Tefferi, A., et al. (2009) · Blood · doi:10.1182/blood-2009-03-209262 · Cited by 4,424
Self-citationA unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
James, C., Ugo, V., Le Couédic, J.-P., Staerk, J., Delhommeau, F., Lacout, C., Garçon, L., Raslova, H., Berger, R., Bennaceur-Griscelli, A., et al. (2005) · Nature · doi:10.1038/nature03546 · Cited by 3,544
Daley, G. Q., Van Etten, R. A., & Baltimore, D. (1990) · Science · doi:10.1126/science.2406902 · Cited by 1,756
Fused transcript of abl and bcr genes in chronic myelogenous leukaemia
Shtivelman, E., Lifshitz, B., Gale, R. P., & Canaani, E. (1985) · Nature · doi:10.1038/315550a0 · Cited by 1,611
Cervantes, F., Dupriez, B., Pereira, A., Passamonti, F., Reilly, J. T., Morra, E., Vannucchi, A. M., Mesa, R. A., Demory, J.-L., Barosi, G., et al. (2009) · Blood · doi:10.1182/blood-2008-07-170449 · Cited by 1,255
Self-citationSafety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis
Verstovsek, S., Kantarjian, H., Mesa, R. A., Pardanani, A. D., Cortes-Franco, J., Thomas, D. A., Estrov, Z., Fridman, J. S., Bradley, E. C., Erickson-Viitanen, S., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002028 · Cited by 1,164
Self-citationEditorial: Some Speculations on the Myeloproliferative Syndromes
DAMESHEK, W. (1951) · Blood · doi:10.1182/blood.v6.4.372.372 · Cited by 1,082
Chromosome Studies on Normal and Leukemic Human Leukocytes
(1960) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/25.1.85 · Cited by 1,069
MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients
Pardanani, A. D., Levine, R. L., Lasho, T., Pikman, Y., Mesa, R. A., Wadleigh, M., Steensma, D. P., Elliott, M. A., Wolanskyj, A. P., Hogan, W. J., et al. (2006) · Blood · doi:10.1182/blood-2006-04-018879 · Cited by 1,056
Self-citationGangat, N., Caramazza, D., Vaidya, R., George, G., Begna, K., Schwager, S., Van Dyke, D., Hanson, C., Wu, W., Pardanani, A., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.2446 · Cited by 1,055
Self-citationTefferi, A., & Vardiman, J. W. (2008) · Leukemia · doi:10.1038/sj.leu.2404955 · Cited by 1,002
Self-citationPassamonti, F., Cervantes, F., Vannucchi, A. M., Morra, E., Rumi, E., Pereira, A., Guglielmelli, P., Pungolino, E., Caramella, M., Maffioli, M., et al. (2010) · Blood · doi:10.1182/blood-2009-09-245837 · Cited by 994
Self-citationTefferi, A., Thiele, J., Orazi, A., Kvasnicka, H. M., Barbui, T., Hanson, C. A., Barosi, G., Verstovsek, S., Birgegard, G., Mesa, R., et al. (2007) · Blood · doi:10.1182/blood-2007-04-083501 · Cited by 862
Self-citationTefferi, A., Vaidya, R., Caramazza, D., Finke, C., Lasho, T., & Pardanani, A. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.9490 · Cited by 608
Self-citationTefferi, A. (2010) · Leukemia · doi:10.1038/leu.2010.69 · Cited by 534
Self-citationInduction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL.
Kelliher, M. A., McLaughlin, J., Witte, O. N., & Rosenberg, N. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.17.6649 · Cited by 514
Barosi, G., Mesa, R. A., Thiele, J., Cervantes, F., Campbell, P. J., Verstovsek, S., Dupriez, B., Levine, R. L., Passamonti, F., Gotlib, J., et al. (2008) · Leukemia · doi:10.1038/sj.leu.2404914 · Cited by 502
Self-citationJacobson, R., Salo, A., & Fialkow, P. (1978) · Blood · doi:10.1182/blood.v51.2.189.189 · Cited by 493
Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis
Pardanani, A., Gotlib, J. R., Jamieson, C., Cortes, J. E., Talpaz, M., Stone, R. M., Silverman, M. H., Gilliland, D. G., Shorr, J., & Tefferi, A. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.8021 · Cited by 400
Self-citationMesa, R. A., Silverstein, M. N., Jacobsen, S. J., Wollan, P. C., & Tefferi, A. (1999) · American Journal of Hematology · doi:10.1002/(sici)1096-8652(199905)61:1<10::aid-ajh3>3.0.co;2-i · Cited by 354
Self-citationElefanty, A. G., Hariharan, I. K., & Cory, S. (1990) · The EMBO Journal · doi:10.1002/j.1460-2075.1990.tb08212.x · Cited by 344
Tefferi, A., Lasho, T. L., Abdel-Wahab, O., Guglielmelli, P., Patel, J., Caramazza, D., Pieri, L., Finke, C. M., Kilpivaara, O., Wadleigh, M., et al. (2010) · Leukemia · doi:10.1038/leu.2010.113 · Cited by 318
Self-citationEZH2 mutational status predicts poor survival in myelofibrosis
Guglielmelli, P., Biamonte, F., Score, J., Hidalgo-Curtis, C., Cervantes, F., Maffioli, M., Fanelli, T., Ernst, T., Winkelman, N., Jones, A. V., et al. (2011) · Blood · doi:10.1182/blood-2011-06-363424 · Cited by 262
Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates
Tefferi, A., Levine, R. L., Lim, K.-H., Abdel-Wahab, O., Lasho, T. L., Patel, J., Finke, C. M., Mullally, A., Li, C.-Y., Pardanani, A., et al. (2009) · Leukemia · doi:10.1038/leu.2009.37 · Cited by 252
Self-citationStam, K., Heisterkamp, N., Grosveld, G., de Klein, A., Verma, R. S., Coleman, M., Dosik, H., & Groffen, J. (1985) · New England Journal of Medicine · doi:10.1056/nejm198512053132301 · Cited by 251
Tefferi, A., Lasho, T. L., Huang, J., Finke, C., Mesa, R. A., Li, C. Y., Wu, W., Hanson, C. A., & Pardanani, A. (2008) · Leukemia · doi:10.1038/sj.leu.2405097 · Cited by 251
Self-citationPomalidomide Is Active in the Treatment of Anemia Associated With Myelofibrosis
Tefferi, A., Verstovsek, S., Barosi, G., Passamonti, F., Roboz, G. J., Gisslinger, H., Paquette, R. L., Cervantes, F., Rivera, C. E., Deeg, H. J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.7356 · Cited by 195
Self-citationCaramazza, D., Begna, K. H., Gangat, N., Vaidya, R., Siragusa, S., Van Dyke, D. L., Hanson, C., Pardanani, A., & Tefferi, A. (2011) · Leukemia · doi:10.1038/leu.2010.234 · Cited by 178
Self-citationTefferi, A., Jimma, T., Sulai, N. H., Lasho, T. L., Finke, C. M., Knudson, R. A., McClure, R. F., & Pardanani, A. (2012) · Leukemia · doi:10.1038/leu.2011.253 · Cited by 172
Self-citationZwei Fälle von Leukämie mit eigenthümlichem Blut- resp. Knochenmarksbefund
Heuck, G. (1879) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/bf01878089 · Cited by 171
Long-Term Outcome of Treatment with Ruxolitinib in Myelofibrosis
Tefferi, A., Litzow, M. R., & Pardanani, A. (2011) · New England Journal of Medicine · doi:10.1056/nejmc1109555 · Cited by 159
Self-citationTefferi, A. (2011) · Blood · doi:10.1182/blood-2010-11-315614 · Cited by 137
Self-citationAbdel-Wahab, O., Pardanani, A., Rampal, R., Lasho, T. L., Levine, R. L., & Tefferi, A. (2011) · Leukemia · doi:10.1038/leu.2011.82 · Cited by 134
Self-citationThe history of myeloproliferative disorders: before and after Dameshek
Tefferi, A. (2007) · Leukemia · doi:10.1038/sj.leu.2404946 · Cited by 127
Self-citationHussein, K., Pardanani, A. D., Dyke, D. L. V., Hanson, C. A., & Tefferi, A. (2009) · Blood · doi:10.1182/blood-2009-08-240135 · Cited by 121
Self-citationLasho, T. L., Finke, C. M., Hanson, C. A., Jimma, T., Knudson, R. A., Ketterling, R. P., Pardanani, A. D., & Tefferi, A. (2011) · Leukemia · doi:10.1038/leu.2011.320 · Cited by 117
Self-citationA phase-2 trial of low-dose pomalidomide in myelofibrosis
Begna, K. H., Mesa, R. A., Pardanani, A. D., Hogan, W. J., Litzow, M. R., McClure, R. F., & Tefferi, A. (2010) · Leukemia · doi:10.1038/leu.2010.254 · Cited by 112
Self-citationTefferi, A., Lasho, T. L., Patnaik, M. M., Finke, C. M., Hussein, K., Hogan, W. J., Elliott, M. A., Litzow, M. R., Hanson, C. A., & Pardanani, A. D. (2009) · Leukemia · doi:10.1038/leu.2009.225 · Cited by 105
Self-citationPatnaik, M. M., Hanson, C. A., Hodnefield, J. M., Knudson, R. A., Dyke, D. L. V., & Tefferi, A. (2010) · Leukemia · doi:10.1038/leu.2010.258 · Cited by 85
Self-citationPardanani, A. D., Finke, C. M., Lasho, T. L., Al‐Kali, A., Begna, K. H., Hanson, C. A., & Tefferi, A. (2011) · Leukemia · doi:10.1038/leu.2011.251 · Cited by 82
Self-citationTefferi, A., Huang, J., Schwager, S. M., Li, C., Wu, W., Pardanani, A. D., & Mesa, R. A. (2007) · Cancer · doi:10.1002/cncr.22630 · Cited by 67
Self-citationSulai, N. H., Jimma, T., Lasho, T. L., Finke, C. M., Knudson, R. A., McClure, R. F., Pardanani, A. D., & Tefferi, A. (2011) · Blood · doi:10.1182/blood.v118.21.1751.1751 · Cited by 61
Self-citationPardanani, A. D., Begna, K. H., Finke, C. M., Lasho, T. L., & Tefferi, A. (2011) · American Journal of Hematology · doi:10.1002/ajh.21972 · Cited by 29
Self-citationNovel CUX1 missense mutation in association with 7q− at leukemic transformation of MPN
Thoennissen, N. H., Lasho, T. L., Thoennissen, G. B., Ogawa, S., Tefferi, A., & Koeffler, H. P. (2011) · American Journal of Hematology · doi:10.1002/ajh.22069 · Cited by 23
Self-citation
Cited by
Guglielmelli, P., Lasho, T. L., Rotunno, G., Mudireddy, M., Mannarelli, C., Nicolosi, M., Pacilli, A., Pardanani, A., Rumi, E., Rosti, V., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.4886 · Cited by 552
Self-citationPardanani, A., Harrison, C., Cortes, J. E., Cervantes, F., Mesa, R. A., Milligan, D., Masszi, T., Mishchenko, E., Jourdan, E., Vannucchi, A. M., et al. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.1590 · Cited by 485
Self-citationMascarenhas, J., Hoffman, R., Talpaz, M., Gerds, A. T., Stein, B., Gupta, V., Szoke, A., Drummond, M., Pristupa, A., Granston, T., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.5818 · Cited by 399
Mesa, R. A., Vannucchi, A. M., Mead, A., Egyed, M., Szoke, A., Suvorov, A., Jakucs, J., Perkins, A., Prasad, R., Mayer, J., et al. (2017) · The Lancet Haematology · doi:10.1016/s2352-3026(17)30027-3 · Cited by 324
Primary myelofibrosis: 2023 update on diagnosis, risk‐stratification, and management
Tefferi, A. (2023) · American Journal of Hematology · doi:10.1002/ajh.26857 · Cited by 305
Self-citation
Metadata
- Authors
- Tefferi, A., Lasho, T. L., Jimma, T., Finke, C. M., Gangat, N., Vaidya, R., Begna, K. H., Al-Kali, A., Ketterling, R. P., Hanson, C. A., & Pardanani, A.
- Venue
- Mayo Clinic Proceedings
- Publisher
- Elsevier BV
- Published
- 2012-01
- Volume
- 87
- Issue
- 1
- Pages
- 25-33
- ISSN
- 0025-6196 (ISSN-L)
- OpenAlex
- W2149055075
- Cited by
- 260
- References
- 45
- FWCI
- 7.08
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.